Please select the option that best describes you:
Topics:
Gynecologic Cancers • Medical Oncology
How do you determine the choice of therapy for platinum resistant ovarian cancer in healthy, good performance status patients?
Two new phase 2 studies this year with apatinib/oral etoposide (AEROC) and sorafenib/topotecan (TRIAS) were released, and NCCN also lists many single agent chemo with or without anti VEGF. How do you think through the options? Or do you opt immediately for clinical trial?
Answer from: at Academic Institution
Platinum-resistant epithelial ovarian cancer is generally defined as relapse less than 6 months following completion of primary or the last platinum-based chemotherapy regimen. Options for therapy include conventional, commercially available drugs or potential clinical trials. If prior genetic testi...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Whenever possible I will consider a clinical trial, but clinical trials are not available for many patients. When a clinical trial is not an option, treating chemotherapy resistant ovarian cancer allows one to practice the ‘art of medicine’. As clinical trials hav...
Comments
at VA Boston Healthcare System
i agree
i agree
Answer from: Medical Oncologist at Community Practice
In a patient with good PS 0-1 who opts for aggressive treatment one could consider the modified (outpatient) Rotterdam protocol of weekly cisplatin and oral etoposide which can yield a median PFS of 6.5 months and OS of 8.5 months. Inpatient version is no more effective. Morgan, RD et. al "An Outpat...